Pyridine → 3,4-dichloro-N-[1-[6-chloro-4-[(E)-N-hydroxy-C-methylcarbonimidoyl]-2-pyridinyl]piperidin-4-yl]-5-methyl-1H-pyrrole-2-carboxamide

HRID 2233940Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 2233940
[C:1]([C:4]1[CH:9]=[C:8]([Cl:10])[N:7]=[C:6]([N:11]2[CH2:16][CH2:15][CH:14]([NH:17][C:18]([C:20]3[NH:21][C:22]([CH3:27])=[C:23]([Cl:26])[C:24]=3[Cl:25])=[O:19])[CH2:13][CH2:12]2)[CH:5]=1)(=O)[CH3:2].N1C=CC=CC=1.Cl.[NH2:35][OH:36]>CCO>[Cl:25][C:24]1[C:23]([Cl:26])=[C:22]([CH3:27])[NH:21][C:20]=1[C:18]([NH:17][CH:14]1[CH2:15][CH2:16][N:11]([C:6]2[CH:5]=[C:4](/[C:1](=[N:35]/[OH:36])/[CH3:2])[CH:9]=[C:8]([Cl:10])[N:7]=2)[CH2:12][CH2:13]1)=[O:19]

Komponenten

5

Versuchsvorschrift

N-[1-(4-Acetyl-6-chloropyridin-2-yl)piperidin-4-yl]-3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamide (Example 115) (49 mg, 0.114 mmol) was dissolved in EtOH (2 ml). Pyridine (74 μl, 0.913 mmol) was added followed by hydroxylamine hydrochloride (63.4 mg, 0.913 mmol). The mixture was stirred at room temperature overnight. The product was purified by semi-prep reverse phase HPLC eluting with CH3CN/H2O (0.1% TFA). (28 mg).

Aufarbeitung

  1. customThe product was purified by semi-prep reverse phase HPLC
  2. washeluting with CH3CN/H2O (0.1% TFA)

Quellen und Nachweise

ORD-Eintrag
ord-89c109adcfb543afa89abb601fc4d102
Quelldatensatz
uspto-grants-2010_05
Patentnummer
US07709503B2

Notizen zur Reaktion

Wird geladen…